Literature DB >> 10666209

Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.

F Osterroth1, A Garbe, P Fisch, H Veelken.   

Abstract

Because of their hypervariable regions and somatic mutations, the antigen receptor molecules of lymphomas (idiotypes) are tumor-specific antigens and attractive targets for antilymphoma immunotherapy. For the optimal induction of human idiotype-specific cytotoxic T cells (CTL), idiotype was presented to CD8(+) peripheral blood mononuclear cells by monocyte-derived autologous dendritic cells (DC) after the endocytosis of idiotype protein or by idiotype-expressing DC. Recombinant idiotype was obtained as a functionally folded Fab fragment by periplasmic expression in Escherichia coli. Idiotype-expressing DC were generated by transduction with recombinant Semliki forest virus vectors encompassing heavy- or light-chain idiotype genes. Autologous lymphoblastoid cell lines stably transfected with Epstein-Barr virus-based idiotype expression vectors were used as target cells to detect idiotype-specific lysis. CTL stimulated with idiotype-loaded DC showed strong specific, CD8-mediated, and major histocompatibility complex (MHC) class I-restricted cytotoxicity against autologous heavy- and light-chain idiotype. In contrast, stimulation with idiotype-transduced DC resulted in only moderate natural killer cell activity. These data confirm the existence of idiotype-specific CTL in patients with lymphoma, define a "good manufacturing practice"-compatible protocol for the generation of these cells without the requirement of viable lymphoma cells, and favor the processing of exogenous antigen over DC transduction for the induction of MHC I-restricted CTL against idiotypes with unknown antigenicity. (Blood. 2000;95:1342-1349)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666209

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.

Authors:  Wen-Kai Weng; Debra Czerwinski; Ronald Levy
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

3.  Evidence for idiotype-directed immunosurveillance is restricted to follicular lymphoma and attributable to somatic hypermutation.

Authors:  Dimitrios Papaioannou; Anna-Maria Strothmeyer; Marcus Dühren-von Minden; Andrea Keppler-Hafkemeyer; Katja Zirlik; Kristina Mikesch; Cornelis A M van Bergen; Marcelo A Navarrete; Hendrik Veelken
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

Review 4.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

Review 5.  Adoptive T-cell therapy for B-cell malignancies.

Authors:  Michael Hudecek; Larry D Anderson; Tetsuya Nishida; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2009-10       Impact factor: 2.929

6.  Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 7.  Immunotherapy for lymphomas.

Authors:  John M Timmerman
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Authors:  Sebastian Belle; Fang Han; Maud Condomines; Olaf Christensen; Mathias Witzens-Harig; Bernd Kasper; Christian Kleist; Peter Terness; Marion Moos; Friedrich Cremer; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  Eur J Haematol       Date:  2008-03-19       Impact factor: 2.997

9.  Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.

Authors:  M Wang; L Sun; J Qian; X Han; L Zhang; P Lin; Z Cai; Q Yi
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

10.  Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Authors:  John M Timmerman; Julie M Vose; Debra K Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W Denney; Ronald Levy
Journal:  Leuk Lymphoma       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.